Tarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $88.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 38.32% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $90.67.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS opened at $63.62 on Monday. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25. The stock has a 50-day moving average of $69.07 and a 200 day moving average of $72.07. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -39.27 and a beta of 0.52. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The business had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million. On average, sell-side analysts forecast that Tarsus Pharmaceuticals will post -0.74 EPS for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 11,964 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $801,588.00. Following the completion of the sale, the chief executive officer directly owned 33,421 shares in the company, valued at $2,239,207. The trade was a 26.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Dianne C. Whitfield sold 4,174 shares of the business’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $279,658.00. Following the sale, the insider owned 35,028 shares of the company’s stock, valued at approximately $2,346,876. This represents a 10.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 79,391 shares of company stock worth $5,432,035. 8.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Fifth Third Bancorp bought a new position in shares of Tarsus Pharmaceuticals during the 1st quarter valued at approximately $345,000. Hsbc Holdings PLC bought a new position in shares of Tarsus Pharmaceuticals during the 1st quarter valued at approximately $686,000. Strs Ohio grew its stake in shares of Tarsus Pharmaceuticals by 4.8% during the 1st quarter. Strs Ohio now owns 8,800 shares of the company’s stock valued at $617,000 after acquiring an additional 400 shares during the period. Capricorn Fund Managers Ltd grew its stake in shares of Tarsus Pharmaceuticals by 18.3% during the 1st quarter. Capricorn Fund Managers Ltd now owns 26,000 shares of the company’s stock valued at $1,824,000 after acquiring an additional 4,018 shares during the period. Finally, Pictet Asset Management Holding SA grew its stake in shares of Tarsus Pharmaceuticals by 1.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 38,198 shares of the company’s stock valued at $2,575,000 after acquiring an additional 620 shares during the period. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.